MedSurgPI LLC congratulates our client, etectRx for the selection of its ID-Cap System to track medication ingestion in an HIV prevention study. Their innovative ingestion event monitoring technology will be used to observe medication adherence for the HIV prevention drug TRUVADA for PrEP®. The ID-Cap System consists of an ingestible sensor that emits a digital message from within the patient for detection by a wearable device. The effectiveness of TRUVADA for PrEP® in reducing the risk of acquiring HIV-1 is strongly correlated with medication adherence. This study will be conducted at Brigham and Women’s Hospital in Boston, led by Peter Chai, MD, MMS, Assistant Professor at Harvard Medical School.
etectRx submitted a premarket notification (510(k)) application with the U.S. Food and Drug Administration (FDA) for its ID-Cap System as an ingestible event marker in late 2018 and anticipates FDA clearance for marketing this year. The ID-Cap System is currently only available for investigational use in IRB-approved clinical studies.
Please visit http://etectrx.com/ if you are interested in learning more about this novel tool to track and manage medication adherence.